Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?

Core Insights - Adverum Biotechnologies (ADVM) has significantly outperformed its Medical sector peers in year-to-date performance, returning 77.3% compared to the average gain of 5.9% for Medical stocks [2][3] - The Zacks Rank system indicates a strong buy recommendation for Adverum Biotechnologies, currently holding a Zacks Rank of 2 [2] - The consensus estimate for Adverum's full-year earnings has increased by 36.5% over the past three months, reflecting improved analyst sentiment [2] Company Performance - Adverum Biotechnologies is part of the Medical - Biomedical and Genetics industry, which consists of 508 stocks and is currently ranked 73 in the Zacks Industry Rank [3] - In contrast, the average performance of stocks in the Medical - Biomedical and Genetics industry has seen a decline of 0.7% this year, indicating that ADVM is outperforming its industry peers [3] Comparison with Other Stocks - Cigna (CI) is another Medical stock that has outperformed its sector, with a year-to-date increase of 20.6% [2] - Cigna belongs to the Medical - HMOs industry, which has experienced a decline of 8.8% year-to-date and is currently ranked 197 [3]